title: Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults.
abstract: OBJECTIVE
  To determine the efficacy of a zoster vaccine on herpes zoster (HR)-related interference with activities of daily living (ADLs) and health-related quality of life (HRQL).
  
  
  METHODS
  Randomized double-blind placebo controlled trial.
  
  
  METHODS
  Twenty-two U.S. sites.
  
  
  METHODS
  Thirty eight thousand five hundred forty-six women and men aged 60 and olcer.
  
  
  METHODS
  HZ burden of interference with ADLs and HRQL using ratings from the Zoster Brief Pain Inventory (ZBPI) and Medical Outcomes Study 12-item Short Form Survey (SF-12) mental component summary (MCS) and physical component summary (PCS) scores. Vaccine efficacy was calculated for the modified-intention-to-treat trial population and solely in participants who developed HZ.
  
  
  RESULTS
  For the modified-intention-to-treat population, the overall zoster vaccine efficacy was 66% (95% confidence interval (CI)=55-74%) for ZBPI ADL burden of interference score and 55% (95% CI=48-61%) for both the SF-12 MCS and PCS scores. Of participants who developed HZ, zoster vaccine reduced the ZBPI ADL burden of interference score by 31% (95% CI=12-51%) and did not significantly reduce the effect on HRQL.
  
  
  CONCLUSIONS
  Zoster vaccine reduced the burden of HZ-related interference with ADLs in the population of vaccinees and in vaccinees who developed HZ. Zoster vaccine reduced the effect of HZ on HRQL in the population of vaccinees but not in vaccinees who developed HZ.
authors.affiliation: Durham Veterans Affairs Medical Center Geriatric Research, Education and Clinical Center and Duke University Medical Centers, Durham, North Carolina, USA.
authors.forename: Kenneth E
authors.initials: KE
authors.lastname: Schmader
authors.forename: Gary R
authors.initials: GR
authors.lastname: Johnson
authors.forename: Patricia
authors.initials: P
authors.lastname: Saddier
authors.forename: Maria
authors.initials: M
authors.lastname: Ciarleglio
authors.forename: William W B
authors.initials: WW
authors.lastname: Wang
authors.forename: Jane H
authors.initials: JH
authors.lastname: Zhang
authors.forename: Ivan S F
authors.initials: IS
authors.lastname: Chan
authors.forename: Shing-Shing
authors.initials: SS
authors.lastname: Yeh
authors.forename: Myron J
authors.initials: MJ
authors.lastname: Levin
authors.forename: Ruth M
authors.initials: RM
authors.lastname: Harbecke
authors.forename: Michael N
authors.initials: MN
authors.lastname: Oxman
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D004311:Double-Blind Method; D005260:Female; D005500:Follow-Up Studies; D006562:Herpes Zoster / Q000150:complications / Q000517:prevention & control* / Q000523:psychology; D053061:Herpes Zoster Vaccine / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008603:Mental Health; D008875:Middle Aged; D009043:Motor Activity / Q000187:drug effects / Q000502:physiology*; D010146:Pain / Q000209:etiology* / Q000523:psychology; D010147:Pain Measurement; D011379:Prognosis; D011446:Prospective Studies; D011788:Quality of Life; D011795:Surveys and Questionnaires; D016896:Treatment Outcome
chemical_list: D053061:Herpes Zoster Vaccine